RxDoctor Payments Data

Alice Townshend, MD

Ophthalmology · Beloit, WINPI 1437169752

Payments from drug & device makers

$1,068in general payments, 2019–2025

Across 27 payments — averaging $39.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$453
  • Sun Pharmaceutical Industries Inc.$141
  • AstraZeneca$125
  • Glaukos Corporation$108
  • AbbVie$73
  • Genentech USA, Inc.$44
  • plus $124 from 5 others

What the payments were for

  • Food & beverage$1,03497%
  • Education$151%
  • Gifts$192%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon11$453
Sun Pharmaceutical Industries Inc.2$141
AstraZeneca1$125
Glaukos Corporation1$108
AbbVie1$73
Genentech USA, Inc.3$44
Lombart Brothers, Inc.2$40
The Cameron-ehlen Group, Inc.3$31
Carl Zeiss Meditec AG1$19
Apellis Pharmaceuticals, Inc.1$18
Regeneron Healthcare Solutions, Inc.1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,068 in reported general payments places this provider in the 65th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$113,076
Medicare patients
474
Services billed
1,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast22$21,755
VyzultaLatanoprostene Bunod24$12,090
MieboPerfluorohexyloctane/Pf13$11,032
LumiganBimatoprost24$8,765
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol24$7,355
Alphagan PBrimonidine Tartrate12$5,137
Brimonidine Tartrate54$4,765
CombiganBrimonidine Tartrate/Timolol11$3,895
Latanoprost435$3,079
TobradexTobramycin/Dexamethasone11$2,955
Loteprednol Etabonate12$2,557
Travoprost13$2,415
Prednisolone Acetate32$1,569
Tobramycin-DexamethasoneTobramycin/Dexamethasone27$1,329
ValacyclovirValacyclovir Hcl13$1,316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Combigan$73$17,79747 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Beloit

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →